豐樂種業(000713.SZ):2021年度淨利潤預增247.19%-296.79%
格隆匯1月17日丨豐樂種業(000713.SZ)公佈2021年年度業績預吿,公司預計實現2021年歸屬於上市公司股東的淨利潤為1.75億元-2億元,比上年同期增長247.19%-296.79%;預計實現扣除非經常性損益後的淨利潤為4000萬元-5000萬元,比上年同期增長83.05%-128.82%。
業績變動原因系:
1、非經常性損益同比增加主要是本年度因土地收儲等因素影響。
2、經常性損益同比增加主要是公司種子業務銷售收入增幅較大,淨利潤同比增加;農化業務因環保投入加大等因素影響,淨利潤同比減少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.